Title:
癌治療薬剤ならびに治療方法
Document Type and Number:
Japanese Patent JP6609867
Kind Code:
B2
Abstract:
An object of the present invention is to reveal a role of a stem cell control factor including Matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained. Additionally, in undifferentiated cancer, the peculiar balance where expression of a stem cell maintenance factor is higher as compared with normal cells is retained. In cancer in which the cancer stem cell controlling mechanism exists, these peculiar balances of a stem cell control factor different from the balance of normal cells exist. In the medicine for treating cancer and the method for treating cancer of the present invention, proliferativeness of cancer is suppressed by breaking down this balance of a stem cell control factor.
Inventors:
Kanoko Shinmori
Application Number:
JP2017524803A
Publication Date:
November 27, 2019
Filing Date:
June 02, 2016
Export Citation:
Assignee:
Kumamoto University
National University Corporation Tokyo Institute of Technology
National University Corporation Tokyo Institute of Technology
International Classes:
A61K31/713; A61K39/395; A61P35/00; A61P35/02; A61P43/00
Foreign References:
| WO2012103455A1 |
Other References:
ULBRIGHT TM. et al.,Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pedia,MODERN PATHOLOGY,2010年,Vol.23,p.972-980,Abstract、Table 2
CHEN Y. et al.,hnRNP K expression and its clinical significance in human Lung cancer tissues,Chin J lung Cancer,2008年,Vol.11,No.2,p.241-245,Abstract
SATO M. et al.,The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the,Oncogene,2002年,Vol.21,p.4822-4829,Abstract
OWONIKOKO TK. et al.,Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer,Cancer Research,Vol.74,No.19,Supp.SUPPL.1.,Abstract Number:922
熊木伸枝他,ヒト精巣胚細胞腫瘍における神経内分泌形質発現の研究:免疫組織化学的手法および共焦点レーザー顕微鏡を用,日本組織細胞化学会総会・学術集会講演プログラム・予稿集,2008年,Vol.49th,p.38
サンペトラ・オルテア他,タンパク質リン酸化酵素阻害薬,実験医学,2009年,Vol.27,No.5(増刊),p.642-647,642ページ右欄
CHEN Y. et al.,hnRNP K expression and its clinical significance in human Lung cancer tissues,Chin J lung Cancer,2008年,Vol.11,No.2,p.241-245,Abstract
SATO M. et al.,The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the,Oncogene,2002年,Vol.21,p.4822-4829,Abstract
OWONIKOKO TK. et al.,Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer,Cancer Research,Vol.74,No.19,Supp.SUPPL.1.,Abstract Number:922
熊木伸枝他,ヒト精巣胚細胞腫瘍における神経内分泌形質発現の研究:免疫組織化学的手法および共焦点レーザー顕微鏡を用,日本組織細胞化学会総会・学術集会講演プログラム・予稿集,2008年,Vol.49th,p.38
サンペトラ・オルテア他,タンパク質リン酸化酵素阻害薬,実験医学,2009年,Vol.27,No.5(増刊),p.642-647,642ページ右欄
Attorney, Agent or Firm:
Kawaguchi